| Literature DB >> 26415912 |
Shihua Wang, Pengchao Xu, Xiaoxia Li, Xiaodong Su, Yunfei Chen, Li Wan, Linyuan Fan, Kan Yin, Yan Liu, Robert Chunhua Zhao1.
Abstract
Mesenchymal stem cells (MSCs) represent a new therapeutic paradigm for a number of diseases because they possess unique biological characteristics such as multipotency, immunomodulation and production of cytokines. Currently, 425 MSC based clinical trials have been conducted for at least 12 kinds of pathological conditions, with many completed trials demonstrating the safety and efficacy of MSCs. Here, we provide an overview of the clinical status of MSCs by searching the public clinical trials database http://clinicaltrials.gov. Particularly, the role of MSCs in clinical trials to treat bone defects and injuries is highlighted.Entities:
Mesh:
Year: 2016 PMID: 26415912 DOI: 10.2174/1874467208666150928153758
Source DB: PubMed Journal: Curr Mol Pharmacol ISSN: 1874-4672 Impact factor: 3.339